Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Phase 3
Recruiting
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Drug: SHR-1316、Paclitaxel (Albumin Bound)、CarboplatinDrug: SHR-1316、ChemotherapeuticDrug: Placebo、Chemotherapeutic
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 537
- Registration Number
- NCT04316364
- Locations
- 🇨🇳
ZheJiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Effect of Low-fat Diet on the Pharmacokinetics of Pyrotinib in Healthy Participants
Phase 1
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04315493
A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04315116
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04305392
- Locations
- 🇨🇳
Meixia Wang, Beijing, Beijing, China
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT04300114
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Phase 3
Recruiting
- Conditions
- Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 474
- Registration Number
- NCT04296370
- Locations
- 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, China
Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04293029
- Locations
- 🇨🇳
The First Affiliated Hospital of Jilin University, Changchun, Jilin, China
A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Adult Subjects
- Interventions
- Drug: SHR1459 fasted in P1, high-fat diet in P2Drug: SHR1459 high-fat diet in P1, fasted in P2
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04291846
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical College, Nanjing, Jiangsu, China
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 1
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT04282070
- Locations
- 🇨🇳
Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China
Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.
Phase 1
Completed
- Conditions
- Healthy Adult Male Volunteers
- Interventions
- Drug: [14C]SHR4640
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04260373
- Locations
- 🇨🇳
First Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China
© Copyright 2025. All Rights Reserved by MedPath